Market Intelligence, Rare Disease Research Tools, and High-Purity Reagents for Mitochondrial Metabolism & Retinitis Pigmentosa Studies.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IDH3B functional studies. Select your component below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type & Mutant) | IDH3B Full-Length WT and RP46 mutant recombinant proteins; High purity (>95%), Sequence Verified, E. coli or HEK293 expressed, Endotoxin <1EU/ug | View IDH3B Products |
| Gene Delivery | IDH3B Promise-ORF / Lentivirus; Full-length ORF for stable cell lines | View IDH3B Products |
| Detection Antibody | Anti-IDH3B Polyclonal or Recombinant Monoclonal Antibody; Sequence-specific, theoretical binding affinity validated | View IDH3B Products |
| Validator | IDH3B siRNA Set; For knockdown verification and cellular assays | View IDH3B Products |
| Complex Partner A | IDH3A (Alpha Subunit); Catalytic core required for NAD+-dependent activity | View IDH3A Products |
| Complex Partner B | IDH3G (Gamma Subunit); Regulatory subunit for allosteric control | View IDH3G Products |
| Comparative Isoform | IDH2 Protein (NADP+-dependent); For comparative enzymology and specificity studies | View IDH2 Products |
| Pathway Control | IDH1 Protein (Cytosolic); Compartment-specific metabolic comparison | View IDH1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterotetrameric Complex Assembly | High-purity IDH3A, IDH3B, IDH3G monomers (>95% purity); Suitable for in vitro reconstitution assays (SPR/BLI) |
| NAD+ Dependent Activity Measurement | Sequence-verified wild-type ensuring cofactor specificity; Theoretical enzymatic parameters provided |
| Isoform & Paralog Selectivity (vs IDH1/IDH2/IDH3A/IDH3G) | IDH Homolog Panel proteins strictly verified by mass spec; human/mouse/cyno orthologs available |
| Disease Variant Functional Validation | Custom mutation service available; Mass spec verified RP46-associated mutant proteins (e.g., rs3178817, rs137853020, rs11542741) |
| Mitochondrial Import Studies | Full-length proteins with native N-termini; Endotoxin controlled for cellular transfection |
| Cross-species Preclinical Evaluation | Human/Mouse/Cyno ortholog proteins with >95% purity |
| Lack of Cellular Target Engagement Controls | Validated siRNA included for specificity checks and knockdown validation |
Live IDH3B R&D Tracker
Market data changes daily. Access the latest global research status directly:
- ➤ View Active Clinical Trials (RP46)
- ➤ Latest Mitochondrial Metabolism Research
- ➤ Disease Mechanism Publications
- ➤ Recent Patent Filings
- ➤ Resistance & Synthetic Lethality Studies
Global Clinical Landscape & Future Outlook
The research landscape for IDH3B is transitioning from basic mitochondrial enzymology to rare disease therapeutic development. As the beta subunit of the NAD+-dependent isocitrate dehydrogenase complex, IDH3B represents a critical node in the TCA cycle. Key drivers:
- Retinitis Pigmentosa 46 (RP46): Biallelic mutations in IDH3B (e.g., rs137853020) cause autosomal recessive RP46, fueling gene therapy programs using AAV-mediated IDH3B delivery.
- Cancer Metabolism: Unlike IDH1/IDH2 gain-of-function mutants, wild-type IDH3 complex is essential for OXPHOS-dependent tumors, opening synthetic lethality opportunities with mitochondrial inhibitors.
- Future R&D Waves: Enzyme replacement strategies face mitochondrial import challenges; small-molecule allosteric modulators targeting IDH3 heterotetramer are in preclinical exploration for metabolic syndrome and rare mitochondrial disorders.
Competitive Modality & Indication Snapshot
| Modality | Research Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy | AAV-mediated IDH3B delivery | Retinitis Pigmentosa (RP46) | High-purity WT protein for potency comparison; Lentivirus/ORF for vector optimization |
| Small Molecule Inhibitors/Activators | Allosteric modulators of IDH3 complex | Cancer metabolism (OXPHOS-dependent tumors), Metabolic syndrome | High-purity WT & mutant proteins for enzymatic selectivity; Thermal shift assays |
| Enzyme Biology | Complex kinetics & regulation | Mitochondrial disorders | Reconstituted heterotetramer (IDH3A+B+G); NAD+/ADP dependence assays |
| Diagnostic Antibodies | Biomarker detection | Inherited retinal diseases | Specificity verification against IDH1/IDH2/IDH3A/IDH3G |
| siRNA/ASO | Knockdown validation | Rare metabolic disorders | Validated siRNA sets for cellular assays and target engagement |